Safety Shot, Inc. (NASDAQ: SHOT) witnessed an impressive 11.66% surge in its stock value, culminating at $4.79 at the close of the preceding trading session. The upswing in Safety Shot’s market performance coincided with the revelation of a strategic initiative by the company.
This week, Safety Shot (SHOT) unveiled its pioneering west coast launch of Safety Shot, an unprecedented beverage globally patented for its capacity to expedite the reduction of blood alcohol content (BAC) and enhance cognitive clarity, facilitating a faster recovery.
Crafted by seasoned industry professionals and substantiated through rigorous research, Safety Shot stands as a nutraceutical functional beverage designed to accelerate the metabolic breakdown of alcohol while supporting recovery and rehydration.
A recent study showcased that the administration of Safety Shot resulted in a noteworthy reduction in blood alcohol content (BAC) within a mere 30 minutes. The average decline in BAC percentage observed with Safety Shot stood at 0.079% BAC/hour, in stark contrast to the control group, which recorded a rate of 0.01% BAC/hour without the consumption of Safety Shot.
The company has initiated a more extensive double-blinded placebo-controlled trial, with anticipated results slated for release in December 2023. To mark this milestone, SHOT extended invitations to members of the media, investors, and influential figures to attend the west coast launch of Safety Shot at Bogies in Westlake Village, California, commencing at 6 PM.
Attendees will have the exclusive opportunity to experience Safety Shot firsthand and engage in a question-and-answer session with the company’s management. This west coast launch aligns with SHOT’s broader strategy, as the company concurrently launches its national online direct-to-consumer sales platform through its official website and Amazon.
Safety Shot has already distributed thousands of Sample Cans and conducted numerous BAC tests, substantiating the belief that experiencing Safety Shot is tantamount to believing in its efficacy.